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ABSTRACT

A method and kit for immobilization of a glycoprotein. The
method may include activating an affinity Support. The affin
ity Support may be activated by reacting the affinity Support
with a compound that is reactive with one or more functional
groups included within the glycoprotein. The method may
also include oxidizing the glycoprotein in which oxidation
conditions are selected to yield an oxidized glycoprotein that
is biologically active and contains a Sufficient number of
reactive aldehyde groups for coupling to a Support. For
example, the oxidized glycoprotein may include five reactive
aldehyde groups. In addition, the method may include react
ing the oxidized-glycoprotein with the activated affinity Sup
port to immobilize the glycoprotein.
13 Claims, 4 Drawing Sheets
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PRODUCING ACTIVE o-ACID

2
which AGP has been immobilized through ionic immobiliza
tion and cross-linking have produced materials with a poor

GLYCOPROTEIN

correlation versus the behavior of soluble AGP. In addition,

MMOBILIZATION METHOD FOR

no successful reports using currently available commercial
CROSS REFERENCE TO RELATED
5 AGP columns for drug-protein binding studies have yet been
APPLICATIONS
reported, despite the widespread use of Such columns for
chiral separations.
The present application claims the benefit under 35 U.S.C.
Therefore, it would be desirable to provide a method of
S 119(e) of U.S. Provisional Patent Application Ser. No. AGP immobilization which produces immobilized AGP
60/672,941, entitled “Immobilization Method for Producing 10 which closely mimics the behavior of AGP in its native form.
Active Alpha 1-Acid Glycoprotein filed Apr. 19, 2005
SUMMARY OF THE INVENTION
which is herein incorporated by reference in its entirety.
Accordingly, the present invention provides a method for

STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH ORDEVELOPMENT

15 the immobilization of AGP based on the mild oxidation of

AGP to generate aldehyde groups in its carbohydrate regions.
This invention was made with government Support under
GM044931 awarded by the National Institute of Health. The
government has certain rights in the invention.

This oxidized form of AGP will then be reacted with a

2O

FIELD OF THE INVENTION

The present invention relates generally to the field of pro
tein immobilization, and particularly to an immobilization
method for producing active C.-acid glycoprotein.
25
BACKGROUND OF THE INVENTION

The binding of serum proteins with drugs has long been of
interest since it affects the transportation and distribution of 30
pharmaceutical agents in the body. One serum protein that is

often involved in this process is O-acid glycoprotein (AGP).
This protein has a carbohydrate content of 45% (w/w). The
mean molecular mass for its native form is approximately
41,000 g/mol. AGP has a single polypeptide chain with up to 35
five carbohydrate moieties. It has been estimated that there
are 12-20 differentforms of AGP in serum due to variations in

its amino acid sequence and the types and numbers of carbo
hydrate groups attached to its polypeptide chain.
Although the exact biological function of AGP is still not
clear, the binding of drugs to AGP has long been of interest
since this may affect the transport and distribution of such
agents in the body. This binding occurs primarily with basic
and neutral Solutes and is thought to mainly involve hydro
phobic interactions; however, coulombic interactions, hydrogen bonding and steric effects may also be present.
Various techniques have been previously used to examine
the binding of drugs to AGP. Examples include equilibrium
dialysis, ultrafiltration, capillary electrophoresis and various
spectroscopic methods. Recent reports with AGP or other
serum proteins like human serum albumin (HSA) have also
explored the use of high performance affinity chromatogra
phy (HPAC) and surface plasmon resonance biosensors for
studying the binding of these proteins with drugs. Advantages
of these later techniques versus traditional Solution-phase
methods include their improved precision, their ease of auto
mation, the convenience with which they can provide equi
librium and kinetic information on drug-protein binding, and
their ability to reuse the same protein preparation for hun

40

45

50

hydrazide-activated support. The behavior of immobilized
AGP that is produced by this method is evaluated by using it
in HPLC columns to examine the binding to R- and S-pro
pranolol, two solutes that have relatively well-characterized
interactions with soluble AGP. The binding of the resulting
immobilized AGP to other drugs is also determined.
In a first aspect of the present invention, a method for
immobilization of a glycoprotein. In an embodiment, the
method may include activating an affinity Support. The affin
ity Support may be activated by reacting the affinity Support
with a compound that is reactive with one or more functional
groups included with the glycoprotein. The method may also
include oxidizing the glycoprotein in which oxidation condi
tions are selected to yield an oxidized glycoprotein that is
biologically active and includes a sufficient number of reac
tive aldehyde groups for coupling to a Support. For example,
the oxidized glycoprotein may include five reactive aldehyde
groups. In addition, the method may include reacting the
oxidized-glycoprotein with the activated affinity Support to
immobilize the glycoprotein.
In accordance with a further aspect of the present inven
tion, a glycoprotein immobilization kit is provided. In Such
aspect, the kit may include an affinity Support for immobiliz
ing the glycoprotein. Further, an activating solution for acti
Vating the affinity Support so that the Support is reactive with
one or more functional groups within the glycoprotein may be
included. For instance, the activating Solution may include a
hyrazide-containing agent. In addition, the kit may include an
oxidizing solution for oxidizing the glycoprotein. In an
aspect, the oxidizing solution is of a composition that yields
an oxidized glycoprotein that is biologically active and con
tains a sufficient number of reactive aldehyde groups (e.g., at
least five reactive aldehyde groups) for coupling to a Support.
Reacting the oxidized-glycoprotein to the activated affinity
Support.

In accordance with an additional aspect of the present
invention, a solid Support for use in a chiral separation assay
55 is provided. The Solid Support may have an hydrazide-acti
vated surface which is reactive with one or more functional

groups of an oxidized alpha one (C.) acid glycoprotein. For
instance, the oxidized-glycoprotein may include at least five
reactive aldehyde groups. The oxidized glycoprotein may be
dreds of samples.
60 reacted with the hydrazide-activated support surface to
One desirable feature in the immobilization of a protein for immobilize the glycoprotein by linking the oxidized-glyco
binding studies is to have the protein in a final form that protein to the hydrazide-activated Support. Such reaction
closely mimics the behavior of its native form. It has been forms a hydrazide-linked alpha one (C) acid glycoprotein
demonstrated in many studies based on HPAC that immobi complex capable of separating a chiral drug.
lized HSA closely mimics the binding of drugs to the soluble 65 It is to be understood that both the foregoing general
form of this protein. However, previous studies with immo description and the following detailed description are exem
bilized AGP have been successful. For instance, reports in plary and explanatory only and are not restrictive of the inven
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tion as claimed. The accompanying drawings, which are
incorporated in and constitute a part of the specification,
illustrate an embodiment of the invention and together with
the general description, serve to explain the principles of the
invention.
BRIEF DESCRIPTION OF THE DRAWINGS

The numerous advantages of the present invention may be
better understood by those skilled in the art by reference to the
accompanying figures in which:

10

FIG. 1 is a flow chart illustration of a method of immobi

lization of a glycoprotein in accordance with an exemplary
embodiment of the present invention;
FIG. 2A is a schematic illustration of the oxidation of

15

O-acid glycoprotein by periodate acid in accordance with an
exemplary embodiment of the present invention;
FIG. 2B is a schematic illustration of the preparation of
hydrazide-activated silica in accordance with an exemplary
embodiment of the present invention;
FIG. 2C is a schematic illustration of the immobilization of
C-acid glycoprotein to a hydrazide-activated Support in
accordance with an exemplary embodiment of the present
invention;

FIG.3A is a schematic illustration of the degree of C.-acid
glycoprotein oxidation at various periodate concentrations in
accordance with an exemplary embodiment of the present
invention, wherein the ratio of Lucifer yellow per C.-acid
glycoprotein (LyCH/AGP) is a measure of the number of
aldehyde groups that are available for coupling on C.-acid
glycoprotein;

25

30

FIG.3B is a schematic illustration of the degree of C.-acid

glycoprotein immobilized to hydrazide-actiated silica after
oxidation at various periodate concentrations in accordance
with an exemplary embodiment of the present invention; and

35

FIG. 4 is a schematic illustration of the rate of immobili

zation for oxidized O-acid glycoprotein in accordance with
an exemplary embodiment of the present invention, wherein
oxidized C.-acid glycoprotein was oxidized with 20 mM
periodate for 10 minutes at room temperature before immo

40

bilization.
DETAILED DESCRIPTION OF THE INVENTION

Reference will now be made in detail to the presently
preferred embodiments of the invention, examples of which
are illustrated in the accompanying drawings.
Referring to FIG. 1, a method 100 for immobilization of a
glycoprotein is provided. In an exemplary embodiment, the
method 100 may include activating an affinity support 102. In
such embodiment, the affinity support may be activated by
reacting the affinity Support with a compound that is reactive
with one or more functional groups included within the gly
coprotein. For instance, for alpha one (C) acid glycoprotein
the affinity Support may be activated with hydrazide, amine,
and other like related agents. In addition, the activated silica
Support may be employed to immobilize a glycoprotein Such
as O-acid glycoprotein.
In further embodiments, the method 100 may include oxi
dizing the glycoprotein 104. In an exemplary embodiment,
oxidation conditions are selected to maximize the activity of
the glycoprotein after oxidation. For example, in order to
maximize the activity of C.-acid glycoprotein, conditions
were chosen Such that excessive damage to the carbohydrate
chains oramino acids within C-acid glycoprotein's structure
did not occur. Further, the oxidation conditions were chosen

so that a sufficient number of aldehyde groups (e.g., at least

45

50
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60

65
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five) were present to couple C-acid glycoprotein to an acti
vated Support. In an embodiment, oxidation conditions may
include reacting the glycoprotein such as C.-acid glycopro
tein with the oxidizing reagent periodate or by using compa
rable oxidative procedures. It is contemplated that periodate
concentrations may range from 0.01 mM to 50 mM, and
preferably from 5 mM to 20 mM.
The method 100 may also include reacting the oxidized
glycoprotein with the activated affinity support 106 to immo
bilize the glycoprotein by linking the oxidized-glycoprotein
to the activated affinity support. In addition, the immobilized
glycoprotein may be washed 108 following reacting the oxi
dized glycoprotein with the activated affinity support to
remove remaining non-reacted compound. Moreover, the
method 100 may include employing the immobilized glyco
protein for separating chiral drugs 110 Such as propranolol
and other like related compounds.
In accordance with a further embodiment of the present
invention, a glycoprotein immobilization kit is provided. In
an exemplary embodiment, the kit may include an affinity
Support for immobilizing the glycoprotein. Further, an acti
Vating solution for activating the affinity Support so that the
Support is reactive with one or more functional groups within
the glycoprotein may be included. For instance, the activating
Solution includes a reagent such as hydrazide, amine, and
other like compounds.
In further exemplary embodiments, the kit may include an
oxidizing solution for oxidizing the glycoprotein. In an
embodiment, the oxidizing Solution is of a composition that
yields an oxidized glycoprotein that is biologically active and
contains a sufficient number of reactive aldehyde groups
(e.g., at least five reactive aldehyde groups) for coupling to a
Support. For example, the oxidizing solution may include
oxidation conditions may include the oxidizing reagent perio
date. It is contemplated that periodate concentrations may
range from 0.01 mM to 50 mM, and preferably from 5 mM to
20 mM. In an alternative embodiment, the oxidizing solution
includes approximately 20 mM sodium acetate and approxi
mately 0.15 mM sodium chloride in a one to one volume to
Volume ratio with periodate concentrations ranging from 5
mM to 20 mM. The kit may also include a washing solution
for washing the activated affinity Support following reacting
the oxidized glycoprotein with the activated affinity support
to remove remaining non-reacted compound on the affinity
Support. For example, the washing solution may include
In an additional exemplary embodiment, a solid Support for
use in a chiral separation assay is disclosed. In an embodi
ment, the Solid Support may have an activated Surface includ
ing hydrazide or amine groups, or other like activated Sur
faces. In the embodiment, the hydrazide-activated surface
may be reactive with one or more functional groups of an
oxidized glycoprotein such as C.-acid glycoprotein. For
instance, this may be obtained through the use of approxi
mately five aldehyde groups in active O-acid glycoprotein,
Such as is produced by oxidizing O-acid glycoprotein with 5
to 20 mM periodate for 10 minutes at pH 7.0 and 4° C.
Reacting the oxidized glycoprotein with the activated Support
Surface immobilizes the glycoprotein by linking the oxidized
glycoprotein to the activated Support. As such, a hydrazide
linked glycoprotein complex capable of separating a chiral
drug (e.g., propanolol and like compounds) is formed.
Some of the specific examples in accordance with exem
plary embodiments of the present invention are provided
below. Further, additional examples in accordance with the
present invention may be found in the publication entitled
“Immobilization of C-acid glycoprotein for chromato
graphic Studies of drug-protein binding. Analytical Bio

US 7,575,908 B1
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5
chemistry, Volume 346, 2005, pages 300 to 310 by Hai Xuan
and David S. Hage, which is herein incorporated by reference
in its entirety.
EXAMPLE1

EXAMPLE 3

Immobilization of Oxidized C.-acid Glycoprotein
5

Preparation of Oxidized C-acid Glycoprotein
FIG. 2A illustrates an exemplary method for preparing
oxidized C.-acid glycoprotein. The conditions chosen for this
reaction vary according to the final degree of oxidation
desired. For instance, 2 to 5 milligram (mg)/milliliter (mL)
O-acid glycoprotein was dissolved in pH 7.0, 20 mM sodium

10

acetate and 0.15 M sodium chloride and combined in a 1:1

(v/v) ratio with 5-20 mM periodic acid in the same buffer. In
Such example, C-acid glycoprotein had a purity of at least
99.0% and was prepared from a pooled serum sample that
included approximately 44% of the F variant of AGP, 29% of

15

the S variant and 27% of the A variant. This mixture was

allowed to react for 10 to 15 minutes at room temperature in
the dark and quenched by adding 0.25 mL ethylene glycol per
milliliter of sample. After this new mixture had reacted for 2
minutes, it was put into a dialysis bag at 4°C. for 2 hours
against 2 liters pH 7.0, 20 mMacetate buffer containing 0.15
M sodium chloride. This was followed by three additional
two-hour dialysis cycles against 2 liter portions of pH 7.0,
0.10 M potassium phosphate buffer.

25

EXAMPLE 2

Analysis of Oxidized C.-acid Glycoprotein
The extent of O-acid glycoprotein oxidation produced by
following the procedures described in Example 1 was moni
tored using Luciferyellow (LyCH) as a labeling agent. In this
technique, a 3 mg/mL solution of LyCH in pH 6.5, 0.10 M
phosphate buffer was mixed with an equal portion of an
oxidized C-acid glycoprotein solution prepared in Example

30

35

buffer at 4° C.
40

45

bance method. To do this, calibration curves were first con

structed at 280 nm for 0-2 mg/mL. C.-acid glycoprotein and at
both 280 and 428 nm for 0-3 mg/mL LyCH in pH 7.4, 0.10 M
phosphate buffer (Note: C.-acid glycoprotein has no measur
able absorbance at 428 nm). These curves gave linear rela

50

tionships with a molar absorptivity of 2.91 (+0.02)x10" M'
cm for O-acid glycoprotein at 280 nm and molar absorp
tivities for LyCH of 2.62 (+0.08)x10" M' cm at 280 nm
and 1.27 (+0.05)x10'M' cm at 428 nm.

For the analysis of LyCH-labeled C.-acid glycoprotein, the
LyCH concentration in each sample was determined by using
the sample's absorbance at 428 nm. The measured LyCH
concentration was then used along with the known molar
absorptivity of LyCH at 280 nm to calculate the absorbance
for LyCH at 280 nm in the labeled sample. This absorbance

buffer. This mixture was shaken for 90 minutes and washed

four times with water. The hydrazide silica was stored under
vacuum at room temperature or in the pH 7.0 phosphate

1 and allowed to react for 2 hours. This mixture was then

applied to a 10 mL Econo-Pac 10DG column (Bio-Rad Labo
ratories) to remove the excess LyCH using pH 7.0, 0.10 M
phosphate buffer as the mobile phase. The labeled AGP was
then collected and dialyzed for several hours at 4°C. against
two to three 2 L portions of pH 7.4, 0.10 Mphosphate buffer.
The amount of LyCH per C-acid glycoprotein in the
labeled sample was determined by using a manual absor

First, hydrazide-activated silica was prepared as shown in
FIG.2B. For example, 1 g of Nucleosil Si-300 obtained from
Alltech (Deerfield, Ill.) was placed in 8.5 mL of pH 5.5, 0.1 M
Sodium acetate buffer and degassed by Sonication under
vacuum for 10 to 15 minutes. Next, 0.20 mL of 3-glycidox
ypropyltrimethoxysilane was added and the solution was
shaken for 5 hours at 90° C. The epoxy silica formed by this
reaction was washed several times with water and a pH 3.0
Sulfuric acid solution. This Support was next Suspended in a
pH 3.0 sulfuric acid solution (using 100 mL of this solution
per gram of silica) and refluxed for 90 minutes. The diol
bonded silica formed as the product was washed with several
portions of water, methanol, and ether and dried overnight
under vacuum at room temperature. To make dihydrazide
activated silica, 1 g of the diol-bonded silica was suspended in
20 mL of a 90% (v/v) acetic acid-water mixture containing 1
g periodic acid. This mixture was Sonicated under reduced
pressure for 10 to 15 minutes and shaken for 2 hours at room
temperature. The resulting aldehyde silica was washed four
times with deionized water or pH 7.0, 0.1 M phosphate buffer
to remove any excess periodic acid. To this aldehyde silica
was then added 50 mL of pH 7.0, 0.1 M phosphate buffer
containing 0.13 g oxalic dihydrazide. This mixture was
shaken for 1 to 2 hours, centrifuged and washed four times
with pH 7.0, 0.1 M phosphate buffer. After activation, the
remaining aldehyde groups were reduced by adding 0.2 g
sodium borohydride in 20 mL of pH 8.0, 0.1 M phosphate

55

60

Oxidized C-acid glycoprotein was immobilized to
hydrazide-activated silica by a procedure illustrated in FIG.
2C. In exemplary studies, a 5 mL portion of pH 7.0, 0.10 M
phosphate buffer containing 1.5 mg/mL oxidized C-acid
glycoprotein was mixed with 0.03 grams of hydrazide-acti
vated silica. This mixture was Sonicated under aspirator
vacuum for 10 minutes to remove any air bubbles from the
Suspension. It was then placed onto a shaker and allowed to
react at 4°C. for up to seven days, with more than two days
being optimum. The reaction was stopped by centrifuging the
reaction mixture and removing the Supernatant. The Support
was next washed several times with pH 7.0, 0.10 Mphosphate
buffer, followed by several additional washings with deion
ized water. Any hydrazide groups remaining on this Support
were removed by adding a 200-fold excess of glyceraldehyde
Versus the Supports original hydrazide content. This mixture
was shaken at 4°C. for 6 hours. The support was thenwashed
several times with pH 7.0, 0.10 M phosphate buffer. The
amount of immobilized C-acid glycoprotein was determined
by comparing the final and initial concentrations of C-acid
glycoprotein in the reaction slurry, using absorbance mea
surements at 280 nm.

was then subtracted from the total absorbance measured for

the sample at this wavelength and used to determine the
concentration of C.-acid glycoprotein. These results were
combined to give the LyCH/C-acid glycoprotein ratio for the
sample, which provided a measure of number of aldehydes
available on the oxidized C-acid glycoprotein for coupling to
hydrazide groups.

EXAMPLE 4

Chromatographic Studies with R- and S-Propranolol
65

The O-acid glycoprotein and hydrazide-activated Sup
ports were downward slurry-packed at 28 MPa (4000 psi) into

US 7,575,908 B1
7
50x4.1 mm I.D. stainless steel columns. These columns were

enclosed in water jackets for temperature control. All Studies,
except those examining the temperature dependence of pro
pranolol—C.-acid glycoprotein binding, were performed at
37°C. The mobile phases and packing solutions were pre- 5
pared using pH 7.4 phosphate buffered saline (PBS, compo
sition: 0.013 M potassium dihydrogen phosphate, 0.053 M
disodium hydrogen phosphate and 0.133 Msodium chloride).
Prior to use, all mobile phases were filtered through a 0.45um 10
cellulose acetate filter and degassed under vacuum for 10 min.
Elution of R- and S-propranolol was detected by monitoring
the absorbance at 225 nm. Zonal elution studies were per
formed on the C-acid glycoprotein column by applying pH

7.4 phosphate buffer solution containing up to 20 uM of the is

desired competing agent while making 20 uIl injections of
R-propranolol or S-propranolol onto the column. At each
concentration of competing agent, three replicate injections
of the desired analyte were made. The propranolol samples
were prepared by dissolving 5.0 LM R- or S-propranolol in
the appropriate mobile phase. All mobile phases containing
propranolol were prepared using the individual enantiomers
or propranolol. The flow rate ranged from 0.8 to 1.5 mL/min,
with no significant changes in the retention factors being

Periodate conc. used for AGP oxidation

Measured property

10 mM

20 nM

50 mM

AGP immobilized

10.2 (+0.2)

15.8 (+0.4)

14.5 (+0.5)

(mg/g silica)
Binding capacity (mgg silica) 6.8 (-0.2) 6.3 (+0.3)
6.8 (+0.3)
Specific activity
0.67 (+0.02) 0.40 (+0.02) 0.47 (+0.03)
(mg/mg AGP)
Association constant
3.1 (+0.2) 3.0 (+0.3) 0.95 (+0.05)

(x10M)

The effect of temperature on the binding of R- and S-pro
pranolol to C-acid glycoprotein columns is presented in
Table 2, below. All of the results presented in Table 2 were
generated by performing self-competition Zonal elution stud
ies at temperatures ranging from 5° C. to 37° C. in pH 7.4
phosphate buffered saline. The numbers in parentheses rep
resent a range of it one standard deviation.

Association equilibrium constant, K. (MAnalyte
S-Propranolol
R-Propranolol

noted under this range of conditions. There was also no 35
observed change in retention with Small variations in the
amount of injected propranolol, indicating that linear elution
conditions were present during these experiments.
The retention times for propranolol were calculated using
a B/As method. The column void volume was determined by
making injections of sodium nitrate onto a column containing
only hydrazide-activated silica while monitoring the absor

40

45

50
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4°C. when not in use.

The effects of oxidation on C-acid glycoprotein are pre
sented in Table 1, below. All of the results presented in Table
1 were determined at 37° C. in pH 7.4 phosphate buffered
saline. The numbers in parentheses represent a range of it one
standard deviation.

25o C.

15° C.

5oC.

4.2 (+0.3) x 10°
2.7 (+0.2) x 10°

5.2 (+1.7) x 10
3.9 (+0.2) x 10°

9 (+2) x 10°
7 (+1) x 10°

11 (+3) x 10
8 (+2) x 10°

The effect of other separation conditions such as pH were
also evaluated. For instance, as the pH decreased from 7.4 to
4.8, the retention factor for R-propranolol decreased from
132 to 17.8 (87%), while the retention factor for S-propra
nolol decreased from 167 to 17.8 (89%). This pH dependent
behavior indicates that the immobilized O-acid glycoprotein
is mimicking the behavior of Such protein in Solution.
EXAMPLE 5

bance at 205 nm. All elution times were corrected for the

extra-column Volume of the chromatographic system, as
determined by making injections of R-propranolol or S-pro
pranolol when no column was present. A correction for the
Small amount of non-specific binding between propranolol
and the hydrazide Support was made by measuring the reten
tion factors for this drug on a column equivalent in size to the
C-acid glycoprotein column, but containing only hydrazide
activated silica. This was measured at each propranolol con
centration in the mobile phase and accounted for 3-15% of the
retention factors noted for propranolol on the C-acid glyco
protein column. The C-acid glycoprotein columns were
found to be stable over at least three months, with only a 5%
change in retention being noted over the course of 50 injec
tions and the application of 4000 column volumes of the
mobile phase. The column was stored in pH 7.4 PBS buffer at

37o C.
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Drug Screening on O-acid Glycoprotein Column

The binding of other drugs to the O.-acid glycoprotein
columns were examined at 25 or 37°C. using pH 7.4, 0.067M
potassium phosphate buffer. These drugs were selected based
on their binding to soluble O-acid glycoprotein. Samples of
each drug were prepared at a concentration of 5 mM. The
injection volume for each sample was 25 LIL, with all samples
being examined in triplicate. The detection wavelengths were
as follows: imipramine, 210 nm; pindolol, 216 nm, trifluop
erazine, 257 mm; and epinephrine and isoproterenol. 203 nm.
All other drugs were monitored at 225 nm. All samples were
used within one day of preparation. The present conditions
yielded a more effective approach for the immobilization of
C-acid glycoprotein with perphenZaine, triflupromazine,
quinidine, and lidocaine when compared to previously
reported findings. Further, the presently employed immobi
lization method gave better performance than thiol-based
immobilization in work with O-acid glycoprotein and other
compounds (e.g., pindolol, quinidine, and propranolol).
Referring to FIG. 3A, the degree of C.-acid glycoprotein
oxidation at various periodate concentrations in accordance
with Example 3 of the present invention is provided. In the

US 7,575,908 B1
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present Example, reactions occurred over a 10 minute time
period at 4°C. in pH 7.0 buffer including 20 mM sodium

10
arrangement of the components thereof without departing
from the scope and spirit of the invention or without sacrific
ing all of its material advantages. The form herein before
described being merely an explanatory embodiment thereof.

acetate and 0.15M sodium chloride. As illustrated in FIG.3A,

an increase in the amount of Lucifer yellow (LyCH) per
C-acid glycoprotein (LyCH/AGP) occurred as the concen
tration of periodate increased from 0 mM and 0.5 mM. Fur
ther, a plateau in the LyCH/AGP ratio was observed between
10 mM and 50 mM. The LyCH/AGP ratio observed under
these conditions indicates that there were up to five usable
aldehyde groups generated per O-acid glycoprotein mol
ecule. It is contemplated that the aldehyde groups are located
in the terminal sialic acid regions with the glycoprotein's
carbohydrate chain since Such regions are known to be the
most Susceptible of periodate oxidation under the presently
employed conditions.
Referring to FIG.3B, the degree of C.-acid immobilized to
hydrazide-actiated silica after oxidation at various periodate
concentrations in accordance with Example 3 of the present

Further, it is to be understood that the claims included below

are merely exemplary of the present invention and are not
intended to limit the scope of coverage which has been
enabled by the written description.
What is claimed is:
10

15

invention is illustrated. As illustrated in FIG. 3B, at 0.05 mM

periodate there was no significant amount of O-acid glyco
protein immobilized even though it was known that Such
conditions gave about one reactive aldehyde group per
C-acid glycoprotein. However, an increase in the amount of
immobilized C.-acid glycoprotein was observed with an
increase in periodate concentration, particularly in the range
of 0.05 mM to 5 mM periodate. This value reached 13.8
milligrams of C-acid glycoprotein per gram silica when 5
mM periodate was used, with similar values being observed
for periodate concentrations up to 50 mM. As illustrated in
FIG. 3A, this is the same range of conditions that gave rise to
five reactive aldehydes per O-acid glycoprotein.
It is contemplated that C.-acid glycoprotein containing
fewer than five aldehyde groups was unable to be immobi
lized effectively to the hydrazide-activated support due to
steric hindrance, where many of these aldehydes groups may
not have been able to come in contact with the supports
Surface. Thus, based upon the present experimental findings,
a preferred embodiment involves oxidizing O-acid glyco
protein by reacting 5-20 mM periodate (typically 10 mM for
optimum reproducibility) for 10 min at 4°C. with 5.0 mg/mL
O-acid glycoprotein in a pH 7.0 buffer containing 20 mM

25

2. The method as claimed in claim 1, wherein the oxidized
30

alpha one (C) acid glycoprotein includes five reactive alde
hyde groups.
3. The method as claimed in claim 1, wherein the activated

affinity support is a hydrazide-activated support.

4. The method as claimed in claim 1, wherein the activated

35

40

affinity Support is an amine-activated Support.
5. The method as claimed in claim 1, further comprising
washing the immobilized alpha one (C) acid glycoprotein
following reacting the oxidized alpha one (C) acid glycopro
tein with the activated affinity Support to remove remaining
non-reacting alpha one (C) acid glycoprotein.

6. The method as claimed in claim 1, wherein oxidation

conditions include reacting the alpha one (C) acid glycopro
tein with 5 mM to 20 mM periodate at room temperature.

sodium acetate and 0.15 M sodium chloride.

Referring to FIG. 4, rate of immobilization for oxidized
C-acid glycoprotein in accordance with an exemplary
embodiment of the present invention in which oxidized
C.-acid glycoprotein was oxidized with 20 mM periodate for
10 minutes at room temperature before immobilization. As
illustrated in FIG. 4, approximately two-thirds of the maxi
mum amount of immobilized C-acid glycoprotein was
obtained within 24 hours, with over ninety percent of maxi
mum coverage being achieved within approximately two
days. Further, longer coupling times did not result in signifi
cant change. Under Such conditions, thirty-three percent of
the added C-acid glycoprotein was immobilized in 24 hours
with half remaining in solution after the immobilization had
reached completion. Therefore, the present conditions
appeared to be adequate to Saturate the available coupling
sites on the Support.
It is believed that the present invention and many of its
attendant advantages will be understood by the foregoing
description. It is also believed that it will be apparent that
various changes may be made in the form, construction and

1. A method for immobilization of an alpha one (C) acid
glycoprotein, comprising:
activating an affinity Support, the affinity Support being
activated by reacting the affinity Support with a com
pound that is reactive with one or more functional
groups including within the one (C) acid glycoprotein;
oxidizing the alpha one (C.) acid glycoprotein, oxidation
conditions being selected to i) yield an oxidized alpha
one (C) acid glycoprotein that includes at least five
reactive aldehyde groups and ii) maximize activity of
said alpha one (C.) acid glycoprotein after oxidation,
wherein said oxidation conditions comprise reacting the
alpha one (C.) acid glycoprotein with 5 mM to 20 mM
periodate for about 10 to 15 minutes;
reacting the oxidized alpha one (C.) acid glycoprotein with
the activated affinity support to immobilize the alpha one
(C.) acid glycoprotein by linking the oxidized alpha one
(C.) acid glycoprotein to the activated affinity Support.

7. The method as claimed in claim 1, wherein the oxidation
45

conditions include reacting the alpha one (C) acid glycopro
tein with 5 mM to 20 mM periodate at about 4°C.
8. The method as claimed in claim 1, wherein the activated

50

affinity Support is a hydrazide-activated silica Support.
9. The method as claimed in claim 1, further comprising
employing the immobilized alpha one (C.) acid glycoprotein
for separating chiral drugs.
10. The method as claimed in claim 9, wherein chiral drugs
include propranolol.
11. The method of claim 1, wherein said oxidation condi

55

tions comprise reacting said alpha one (C.) acid glycoprotein
at a concentration of about 2 to 5 milligram/milliliter.
12. The method of claim 1, wherein said oxidation condi

tions comprise reacting said alpha one (C) acid glycoprotein
at about pH 7.0.
13. The method of claim 1, wherein said oxidation condi
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tions comprise reacting said alpha one (C) acid glycoprotein
at about pH 7.0 for about 10 minutes at about 4°C.
k

k

k

k

k

